What types of organoid models are available for me in the Crown Bioscience biobank?
Our biobank offers over 200 patient-derived organoid (PDO) models for six oncological indications. Additionally, we have patient-matched normal models available for four indications, as well as patient-matched primary and metastatic models. Furthermore, we provide irritable bowel disease (IBD) PDO models for testing anti-inflammatory treatments and regenerative medicine approaches.
Are there PDX-Derived Organoid (PDXO) models available?
Yes, we generate PDXO models using our extensive patient-derived xenograft (PDX) biobank. Currently, we have around 400 PDXO models available from 18 indications, and our selection is continuously expanding. Additionally, we provide in vivo models that match the PDXO models for validation or efficacy studies.
What advantages do your PDO and PDXO models offer?
Our PDO and PDXO models have preserved genetic backgrounds and gene expressions compared to their parental models. They show high correlations over passaging, ensuring consistency and reliability of data. These models exhibit similar responses to pharmacological profiling as their in vivo counterparts, making them highly predictive for drug responses.
How does Crown Bioscience ensure the quality and reliability of their organoid models?
Authentication analyses are conducted to ensure the absence of genetic drift and contamination, ensuring that historical data from primary tissues are comparable. We verify the preservation of genetic background and gene expression in our PDXO models, and we have found that the responses between in vitro and in vivo models during pharmacological profiling are similar. Following standard procedures for organoid culture, including careful passaging and freezing methods, is crucial for maintaining long-term and high-quality cultures.
What services does Crown Bioscience offer in relation to organoids?
As a Contract Research Organization (CRO), we provide in vitro, in vivo, and biomarker analysis services. Organoids can be used for early-stage drug discovery, conducting high-throughput screens of thousands of compounds. Additionally, they are utilized in the drug development stage to test lead compounds for efficacy, safety, side effects, combinatorial effects, and pharmacokinetics. The high predictivity of organoids in drug response allows for in vitro clinical trials and downstream biomarker analysis, enabling the identification of responsive and non-responsive patient populations.
What advancements can I expect in Crown Bioscience's organoid capabilities?
We are planning to release large panel screening capabilities in the third quarter of this year. This will involve the use of organoids from different indications with various backgrounds.
How will Crown Bioscience accelerate my research timelines and reduce costs?
Our upcoming release of large panel screening capabilities using organoids from different indications will fast-track research activities by shortening timelines and reducing costs. These capabilities will enable you to efficiently screen a wide range of compounds and make informed decisions about lead compounds.
Can Crown Bioscience provide additional support for my complex research applications?
Sure, we offer co-culturing assays with immune and stromal cells to extend the applications of organoid models. We currently provide several well-characterized co-culture assays and plan to further expand the co-culture complexity in the near future. The use of CRISPR/Cas technology enables the development of knock-down, knock-out, and knock-in models for specific applications.
Can I visualize and quantify complex morphology and biological changes in organoid models?
Certainly! We employ high-content imaging technology, enabling visualization and quantification of complex morphological and biological changes in organoids. This provides a deeper understanding of the models and facilitates comprehensive analyses.
How will working with Crown Bioscience contribute to personalized medicine research?
Organoids are highly predictive and reproducible in vitro models, poised to revolutionize research in the field of personalized medicine. Crown Bioscience's organoid models allow for the identification of patient populations, facilitating personalized treatment approaches.
Visit OrganoidBase™ to leverage the power of organoids and advance your research towards improving patient outcomes.